Core Viewpoint - Jingtai Holdings (02228) is expected to achieve significant financial improvement by mid-2025, with a projected consolidated revenue of no less than RMB 500 million, representing an increase of at least approximately 387% year-on-year [1] Financial Performance - The company anticipates turning from a loss to a profit, with a net profit of no less than RMB 50 million for the mid-2025 period [1] - Adjusted net profit (non-IFRS measure) is expected to be no less than RMB 120 million [1] - This will mark the company's first half-year profit [1] Strategic Partnerships - The expected financial improvement is primarily due to the collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and comprehensive "AI + Robotics" technology [1] - The partnership has led to significant revenue growth, with an initial payment of USD 51 million recognized as revenue for the mid-2025 period, contributing substantially to the company's earnings [1] - According to the agreement with DoveTree, the company is entitled to receive further payments, which will be recognized as revenue in batches in the future [1]
港股异动 晶泰控股(02228)涨超8% 预计上半年营收同增至少约387% 公司首次实现半年盈利